Bayer announced initiation of a phase I clinical trial with ... tolerability and preliminary efficacy of BAY3498264 as a combination therapy in patients with advanced KRAS G12C-mutated solid tumours.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback